Bridgebio Pharma Inc (BBIO) Stock Price, Quote & News

Company Profile

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 391 9740

Website: bridgebio.com

Address:

3160 Porter Drive, Suite 250, Palo Alto, United States

sampeper May. 13 at 10:57 AM

$BBIO BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 - Slideshow https://seekingalpha.com/article/4903575-bridgebio-pharma-inc-bbio-presents-at-bank-of-america-global-healthcare-conference-2026

0 · Reply

sampeper May. 13 at 10:56 AM

$BBIO J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating https://news.futunn.com/en/post/72956687/jp-morgan-maintains-bridgebio-pharma-bbious-with-buy-rating?level=1&data_ticket=1778669748776694

0 · Reply

MarketBeat May. 13 at 5:06 AM

https://marketbeat.com/a/8651299/ $BBIO BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

0 · Reply

sampeper May. 12 at 3:31 PM

$BBIO BridgeBio (BBIO) Positioned for Growth According to JPMorgan Analysis . Analysts from JPMorgan anticipate a significant upward trajectory towards the $90 to $100 range, attributing this potential to the strong launch of Attruby and the company's efforts to broaden its sales through a robust late-stage pipeline. https://www.gurufocus.com/news/8851356/bridgebio-bbio-positioned-for-growth-according-to-jpmorgan-analysis

0 · Reply

sampeper May. 12 at 1:27 PM

$BBIO BridgeBio submits NDA to FDA for encaleret for individuals living with ADH1 https://www.marketscreener.com/news/bridgebio-submits-nda-to-fda-for-encaleret-for-individuals-living-with-adh1-ce7f5bdedd8ff324

0 · Reply

sampeper May. 12 at 1:25 PM

$BBIO BridgeBio Files New Drug Application for Rare Calcium Disorder Treatment https://www.marketscreener.com/news/bridgebio-files-new-drug-application-for-rare-calcium-disorder-treatment-ce7f5bdedd8ef521

0 · Reply

sampeper May. 12 at 1:25 PM

$BBIO HC Wainwright Issues Optimistic Outlook for BBIO Earnings https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-optimistic-outlook-for-bbio-earnings-2026-05-12/#google_vignette

0 · Reply

sampeper May. 12 at 1:23 PM

$BBIO breaking news: BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 https://markets.businessinsider.com/news/stocks/bridgebio-submits-nda-to-fda-for-encaleret-for-individuals-living-with-adh1-1036142634

0 · Reply

sampeper May. 12 at 11:10 AM

$BBIO BridgeBio Pharma : BBIO - Encaleret - ADH1 - Primary Results from Phase 3 CALIBRATE Trial https://www.marketscreener.com/news/bridgebio-pharma-bbio-encaleret-adh1-primary-results-from-phase-3-calibrate-trial-ce7f5bded881f122

0 · Reply

sampeper May. 12 at 11:06 AM

$BBIO BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial https://www.clinicaltrialsarena.com/news/bridgebio-attruby-acoramidis-attr-cm-hf-2026/

0 · Reply

BridgeBio Pharma Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T13:20:39.000Z - 1 day ago

BridgeBio shares have ‘clear path’ to $90s, says JPMorgan

May 12, 2026, 7:30 AM EDT - 1 day ago

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

2026-05-11T19:59:22.000Z - 1 day ago

BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026

May 11, 2026, 9:30 AM EDT - 2 days ago

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

2026-05-11T10:45:29.000Z - 2 days ago

BridgeBio price target raised to $110 from $100 at H.C. Wainwright

May 8, 2026, 4:01 PM EDT - 4 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-05-08T18:38:04.000Z - 4 days ago

BridgeBio price target raised to $130 from $125 at Evercore ISI

2026-05-08T14:57:27.000Z - 5 days ago

BridgeBio price target lowered to $94 from $98 at Morgan Stanley

2026-05-08T11:59:17.000Z - 5 days ago

BridgeBio price target raised to $114 from $100 at Bernstein

2026-05-08T10:21:40.000Z - 5 days ago

BridgeBio files automatic mixed securities shelf

May 7, 2026, 4:30 PM EDT - 5 days ago

BridgeBio Pharma Earnings Call Transcript: Q1 2026

May 7, 2026, 4:01 PM EDT - 5 days ago

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

2026-05-07T03:52:09.000Z - 6 days ago

BridgeBio receives regulatory approval in Brazil for Beyonttra

May 6, 2026, 4:01 PM EDT - 6 days ago

BridgeBio to Participate in May and June Investor Conferences

May 6, 2026, 7:30 AM EDT - 7 days ago

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

May 5, 2026, 7:30 AM EDT - 8 days ago

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

May 4, 2026, 7:30 AM EDT - 9 days ago

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

Apr 30, 2026, 7:30 AM EDT - 13 days ago

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

2026-04-29T13:59:42.000Z - 14 days ago

BridgeBio price target raised to $102 from $95 at Truist

2026-04-28T17:50:56.000Z - 14 days ago

BofA ups BridgeBio price target, cites exclusivity ‘disappointment’ for pullback

PFE

2026-04-28T14:49:44.000Z - 15 days ago

BridgeBio turns negative after Pfizer details tamidis settlement

PFE

2026-04-28T14:48:41.000Z - 15 days ago

BridgeBio jumps 12% to $83.18 as Pfizer confirms tafamidis settlement

PFE

2026-04-28T14:25:34.000Z - 15 days ago

BridgeBio could trade to $90-$110 on Pfizer settlement, says Mizuho

PFE

Mar 30, 2026, 3:30 PM EDT - 6 weeks ago

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Mar 30, 2026, 7:30 AM EDT - 6 weeks ago

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

Mar 23, 2026, 7:30 AM EDT - 7 weeks ago

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

Mar 11, 2026, 2:00 PM EDT - 2 months ago

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

Mar 11, 2026, 12:30 PM EDT - 2 months ago

BridgeBio Pharma Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 1:00 PM EDT - 2 months ago

BridgeBio Pharma Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 7:30 AM EST - 2 months ago

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Mar 2, 2026, 3:50 PM EST - 2 months ago

BridgeBio Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:30 PM EST - 2 months ago

BridgeBio Pharma Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:01 PM EST - 2 months ago

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

Feb 23, 2026, 7:30 AM EST - 2 months ago

BridgeBio to Participate in March Investor Conferences

Feb 17, 2026, 7:30 AM EST - 3 months ago

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

Feb 12, 2026, 8:00 AM EST - 3 months ago

BridgeBio Pharma Transcript: Study result

Feb 12, 2026, 7:30 AM EST - 3 months ago

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

Jan 27, 2026, 5:10 PM EST - 3 months ago

CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 1:00 AM EST - 4 months ago

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

Jan 14, 2026, 4:01 PM EST - 4 months ago

BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

Jan 12, 2026, 10:30 AM EST - 4 months ago

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 4 months ago

BridgeBio Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 8:00 AM EST - 4 months ago

BridgeBio Pharma Transcript: Investor Update

Jan 5, 2026, 7:30 AM EST - 4 months ago

BridgeBio to Participate in the J.P. Morgan Healthcare Conference

Jan 2, 2026, 7:30 AM EST - 4 months ago

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

Dec 3, 2025, 3:00 PM EST - 5 months ago

BridgeBio Pharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:30 AM EST - 5 months ago

BridgeBio Pharma Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 6 months ago

BridgeBio to Participate in December Investor Conferences

Nov 18, 2025, 11:00 AM EST - 6 months ago

BridgeBio Pharma Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 1:15 PM EST - 6 months ago

BridgeBio Pharma Transcript: UBS Global Healthcare Conference 2025

Nov 8, 2025, 10:41 AM EST - 6 months ago

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Nov 7, 2025, 1:00 PM EST - 6 months ago

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Nov 4, 2025, 7:30 AM EST - 6 months ago

BridgeBio to Participate in November Investor Conferences

Nov 3, 2025, 9:58 AM EST - 6 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Nov 3, 2025, 7:30 AM EST - 6 months ago

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Oct 29, 2025, 4:30 PM EDT - 6 months ago

BridgeBio Pharma Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:01 PM EDT - 6 months ago

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

Oct 29, 2025, 8:00 AM EDT - 7 months ago

BridgeBio Pharma Transcript: Study Result

Oct 29, 2025, 7:00 AM EDT - 7 months ago

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

Oct 28, 2025, 4:01 PM EDT - 7 months ago

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

Oct 27, 2025, 8:00 AM EDT - 7 months ago

BridgeBio Pharma Transcript: Study Result

Oct 27, 2025, 7:00 AM EDT - 7 months ago

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

Oct 24, 2025, 4:01 PM EDT - 7 months ago

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Sep 28, 2025, 11:15 AM EDT - 8 months ago

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

Sep 22, 2025, 7:30 AM EDT - 8 months ago

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

Sep 10, 2025, 8:00 AM EDT - 8 months ago

BridgeBio Pharma Transcript: Investor Update

Sep 8, 2025, 3:20 PM EDT - 8 months ago

BridgeBio Pharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 6, 2025, 2:30 PM EDT - 8 months ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

Sep 4, 2025, 2:10 PM EDT - 8 months ago

BridgeBio Pharma Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:30 AM EDT - 9 months ago

BridgeBio Pharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 9 months ago

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

Sep 2, 2025, 7:30 AM EDT - 9 months ago

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Aug 30, 2025, 7:15 AM EDT - 9 months ago

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

Aug 27, 2025, 7:30 AM EDT - 9 months ago

BridgeBio to Participate in September Investor Conferences

Aug 25, 2025, 7:30 AM EDT - 9 months ago

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Aug 19, 2025, 5:30 PM EDT - 9 months ago

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

Aug 5, 2025, 4:30 PM EDT - 10 months ago

BridgeBio Pharma Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 10 months ago

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Jul 30, 2025, 12:37 PM EDT - 10 months ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

AMGN INSM

Jul 23, 2025, 7:30 AM EDT - 10 months ago

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

Jul 22, 2025, 7:30 AM EDT - 10 months ago

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

Jul 11, 2025, 8:00 AM EDT - 10 months ago

BridgeBio Pharma Transcript: Study Update

Jul 7, 2025, 6:29 PM EDT - 11 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BMRN GILD INSM XBI

Jun 30, 2025, 7:30 AM EDT - 11 months ago

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

sampeper May. 13 at 10:57 AM

0 · Reply

sampeper May. 13 at 10:56 AM

0 · Reply

MarketBeat May. 13 at 5:06 AM

https://marketbeat.com/a/8651299/ $BBIO BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

0 · Reply

sampeper May. 12 at 3:31 PM

0 · Reply

sampeper May. 12 at 1:27 PM

0 · Reply

sampeper May. 12 at 1:25 PM

0 · Reply

sampeper May. 12 at 1:25 PM

$BBIO HC Wainwright Issues Optimistic Outlook for BBIO Earnings https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-optimistic-outlook-for-bbio-earnings-2026-05-12/#google_vignette

0 · Reply

sampeper May. 12 at 1:23 PM

0 · Reply

sampeper May. 12 at 11:10 AM

0 · Reply

sampeper May. 12 at 11:06 AM

$BBIO BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial https://www.clinicaltrialsarena.com/news/bridgebio-attruby-acoramidis-attr-cm-hf-2026/

0 · Reply

CapitalMonk May. 11 at 8:03 PM

$BBIO Price: $64.68 (-4.02%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.18% RSI: 22.4 | Momentum: Strong Downside Volume: +14.5% vs avg Volatility: 2.16% Support: $63.88 | Resistance: $84.75 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

sampeper May. 11 at 4:20 PM

$BBIO news: BridgeBio Pharma (Nasdaq: BBIO) reported new Phase 3 ATTRibute-CM data showing that acoramidis increased serum transthyretin (sTTR) early and significantly reduced intra-individual sTTR variability versus placebo, both linked to lower all-cause mortality. Acoramidis also cut outpatient worsening heart failure risk by 41% and reduced cardiovascular hospitalizations by 34% versus tafamidis in an indirect comparison. The therapy consistently blunted NT-proBNP increases, preserved Kansas City Cardiomyopathy Questionnaire scores, and improved or maintained heart failure-related health status. Acoramidis, a near-complete (≥90%) TTR stabilizer, is approved as Attruby in the US and BEYONTTRA in multiple global markets for ATTR-CM. https://www.stocktitan.net/news/BBIO/acoramidis-continues-to-demonstrate-disease-modifying-effects-in-bqwjm5liwwfy.html

0 · Reply

sampeper May. 11 at 4:19 PM

$BBIO Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure https://www.stocktitan.net/news/BBIO/acoramidis-continues-to-demonstrate-disease-modifying-effects-in-bqwjm5liwwfy.html

0 · Reply

sampeper May. 11 at 4:19 PM

$BBIO Acoramidis continues to demonstrate disease-modifying effects in ATTR-CM https://www.marketscreener.com/news/acoramidis-continues-to-demonstrate-disease-modifying-effects-in-attr-cm-ce7f5bd9d881f22d

0 · Reply

sampeper May. 11 at 4:18 PM

$BBIO H.C. Wainwright raises BridgeBio stock price target to $110 on revenue beat https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-bridgebio-stock-price-target-to-110-on-revenue-beat-93CH-4676037

0 · Reply

MikeyNJ May. 11 at 2:30 PM

$BBIO Company firing on all cylinders. Analyst's targets raised to $100+. It's amazing how much the PFE tafamidis patent case is weighing on BBIO. I'd use it as a good opportunity to buy.

2 · Reply

sampeper May. 11 at 1:14 PM

$BBIO BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, HC Wainwright Analyst Says https://www.marketbeat.com/instant-alerts/bridgebio-pharma-nasdaqbbio-stock-price-expected-to-rise-hc-wainwright-analyst-says-2026-05-11/#google_vignette

0 · Reply

sampeper May. 10 at 3:54 AM

$BBIO BridgeBio Pharma Reports 392 Percent Revenue Surge for ATTRUBY https://www.harianbasis.co/en/bridgebio-pharma-attruby-revenue-growth#google_vignette

0 · Reply

sampeper May. 8 at 6:00 PM

$BBIO BridgeBio price target raised to $114 from $100 at Bernstein https://www.tipranks.com/news/the-fly/bridgebio-price-target-raised-to-114-from-100-at-bernstein-thefly-news

0 · Reply

sampeper May. 8 at 5:00 PM

$BBIO BBIO Maintained by Evercore ISI Group -- Price Target Raised to $130 https://www.gurufocus.com/news/8846276/bbio-maintained-by-evercore-isi-group-price-target-raised-to-130

0 · Reply

MorganHoratio May. 8 at 1:24 PM

Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $ARM - 1,960,784 shares $ASTS - 8,943,486 $AUTL - 698,262 $BEAM - 321,604 $BBIO - 2,823,126 Google's Q1 13F is a masterclass in Space, Silicon, and AI Bio! The standout is definitely the 8.9M share stake in $ASTS. Despite the looming SpaceX IPO, Google is doubling down on this "Space-based Cell Tower"—a clear play for global Gemini AI dominance. $ARM remains the bedrock of its custom silicon (Axion) strategy, while $BEAM and $BBIO highlight a massive pivot into AI-driven drug discovery. Do you think $ASTS is Google's ultimate strategic hedge against Starlink in 2026? Which of these deep-tech plays are you adding to your watchlist?

1 · Reply

sampeper May. 8 at 12:32 PM

$BBIO BridgeBio (NASDAQ: BBIO) surges to $194.5M Q1 revenue and okays $500M buyback https://www.stocktitan.net/sec-filings/BBIO/8-k-bridge-bio-pharma-inc-reports-material-event-397badb0b5ee.html

0 · Reply

Market Cap	12.67B
Revenue (ttm)	502.08M
Net Income (ttm)	-724.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-144.39%
Debt to Equity Ratio	-0.85

Volume	2,410,000
Avg Vol	2,370,668
Day's Range	N/A - N/A
Shares Out	195.86M
Stochastic %K	24%
Beta	1.02
Analysts	Strong Sell
Price Target	$104.00